Patents Examined by Lisa V. Cook
  • Methods for predicting post-operative recurrence of Crohn's disease
    Patent number: 10697961
    Abstract: The present invention provides methods for predicting post-operative recurrence of Crohn's disease (CD) in a subject. With the present invention it is possible to predict whether a patient undergoing surgical treatment of CD is at risk of developing histological, radiographic, endoscopic, and/or clinical recurrence of the disease.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 30, 2020
    Assignees: Prometheus Biosciences, Inc., Katholieke Universiteit Leuven
    Inventors: Steven Lockton, Marc Ferrante, Severine Vermiere, Sharat Singh
  • LKB1 related diagnostics and treatments of cancer
    Patent number: 10684290
    Abstract: Described herein are methods and compositions for the diagnosis, prognosis, selection of treatment and treatment of cancer, and particularly, of lung cancer such as non-small cell lung cancer. Embodiments of the present invention involve the detection of LKB1 levels and sensitivity to endoplasmic reticulum (ER) stress. Treatment can be made through the administration of ER stress activators.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: June 16, 2020
    Assignee: Dignity Health
    Inventor: Landon J. Inge
  • Protein L based bioassay method for determining presence of soluble antibodies in a sample and kit therefor
    Patent number: 10670607
    Abstract: This invention relates to bioassay method wherein the presence of a specific soluble antibody in a sample of a bodily fluid, plasma or serum, of an animal, including human, is qualitatively and/or quantitatively determined. The method employs, a first group labelled with an energy donor and a second group labelled with an energy acceptor; the first group, or second group, comprising an antigen of the soluble antibody and the second group, or first group, respectively, comprising a Fab binding moiety capable of binding to a Fab region of antibodies of said animal. The donor and the acceptor form an energy transfer pair capable of energy transfer. The invention further comprises a kit for the bioassay method.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: June 2, 2020
    Assignee: University of Helsinki
    Inventors: Klaus Hedman, Jussi Hepojoki, Satu Hepojoki, Antti Vaheri, Olli Vapalahti
  • Method for evaluating the risk of mortality in patients who exhibit a systemic inflammatory response syndrome (SIRS) or sepsis
    Patent number: 10663472
    Abstract: The invention provides a method of evaluating the risk of mortality in patients who present a systemic inflammatory response (SIRS) or septic syndromes, comprising measuring the expression of sCD127 in a biological sample.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: May 26, 2020
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON
    Inventors: Guillaume Monneret, Fabienne Venet, Alain Lepape, Julie Demaret, Astrid Villars-Mechin
  • Activation of bioluminescence by structural complementation
    Patent number: 10648971
    Abstract: Provided herein are compositions and methods for the assembly of a bioluminescent complex from two or more non-luminescent (e.g., substantially non-luminescent) peptide and/or polypeptide units. In particular, bioluminescent activity is conferred upon a non-luminescent polypeptide via structural complementation with another, complementary non-luminescent peptide.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: May 12, 2020
    Assignee: Promega Corporation
    Inventors: Andrew S. Dixon, Lance Encell, Mary Hall, Keith Wood, Monika Wood, Marie Schwinn, Brock F. Binkowski, Hicham Zegzouti, Nidhi Nath, Subhanjan Mondal, Said Goueli, Poncho Meisenheimer, Thomas Kirkland, James Unch, Dileep K. Pulukkunat, Matthew Robers, Melanie Dart, Thomas Machleidt
  • Prediction of fertility in males
    Patent number: 10641763
    Abstract: A method for evaluating sperm fertility. The method includes the steps of obtaining a sample of sperm from an animal of a species; staining the sample with a fluorescent DNA-binding dye; collecting at least one image of the stained sample; determining an edge of a nucleus of at least one sperm within the stained sample in the at least one image; measuring an intensity of the DNA-binding dye within an area defined by the edge of the nucleus of the at least one sperm; determining an average intensity per unit area of the area defined by the edge of the nucleus of the at least one sperm; comparing the average intensity per unit area to an average intensity per unit area for high-fertility sperm and low-fertility sperm of the same species to determine if the sample has high or low fertility.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: May 5, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: John Parrish
  • In vitro method for predicting, diagnosing and monitoring in therapeutic follow up lupus nephritis
    Patent number: 10620201
    Abstract: The present invention relates to an in vitro method for the prediction and/or diagnose of lupus nephritis in subjects affected or potentially affected by systemic lupus erythematosus, an in vitro method for monitoring a therapy against lupus nephritis in subjects affected or potentially affected by systemic lupus erythematosus and a kit for the prediction of the progression of lupus nephritis and/or for monitoring a therapy against lupus nephritis in subjects affected or potentially affected by lupus erythematosus.
    Type: Grant
    Filed: January 19, 2015
    Date of Patent: April 14, 2020
    Assignee: PAD 4 DI MARIA ADELE SILVIA DENEGRI S.A.S.
    Inventors: Gian Marco Ghiggeri, Luca Ghiggeri
  • Method for predicting the risk of getting cancer or diagnosing cancer in a subject
    Patent number: 10605812
    Abstract: A method for predicting the risk of getting cancer in a subject that does not suffer from cancer or alternatively diagnosing cancer in a subject, where the method includes determining the level of Pro-Tachykinin, its splice variants or fragments thereof of at least 5 amino acids, where the fragments including Substance P and Neurokinin, in a bodily fluid obtained from the subject; and correlating the level of Pro-Tachykinin, its splice variants or fragments thereof with a risk for getting cancer, wherein a reduced Pro-Tachykinin level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein a reduced level is correlated with the diagnosis of cancer.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: March 31, 2020
    Assignee: SphingoTec GmbH
    Inventor: Andreas Bergmann
  • Immunochromatographic analysis method
    Patent number: 10591470
    Abstract: An object is to provide an immunochromatographic analysis method capable of shortening the developing time without decreasing the detection sensitivity, and also capable of reducing the return of the liquid of a developed component, and a method for detecting a detection target contained in an analyte using an immunochromatographic analysis device including an absorption part composed of glass fiber, wherein the analyte and a labeling substance are developed in a chromatography medium part as a mobile phase in the presence of a nonionic surfactant, and the detection target is detected in a detection part is provided.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: March 17, 2020
    Assignee: TANAKA KIKINZOKU KOGYO K.K.
    Inventors: Hisahiko Iwamoto, Kazuyoshi Mochiduki, Daisuke Ito, Yuya Kato
  • Device and method for detection of analytes
    Patent number: 10564166
    Abstract: A detection device and associated systems and methods for detecting analytes from a multiplex reaction are described. In particular, a device for conducting at least one detection reaction using a modified ELISA method including a surface with a detection region and a reference region, a detection sensor, and a light source. The detection device may include a complementary metal-oxide-semiconductor (CMOS) image sensor. The device may be used to measure and report discrete quantities or combinations of discrete analytes, providing information to aid in the prognosis and/or diagnosis of altered states of health in vertebrates.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: February 18, 2020
    Assignee: Xcellcure, LLC
    Inventors: Leah Amir, Gary Anderson
  • Kidney disease biomarker
    Patent number: 10545157
    Abstract: The disclosure provides methods and solid states devices for detecting and staging chronic kidney disease in a patient, where the levels of biomarkers in a sample obtained from a patient are elevated or reduced compared to the levels in a sample obtained from healthy subject. In addition, the disclosure provides the use of methods and solid state devices for measurement of specific biological markers for determining the efficacy of a treatment for chronic kidney disease and for determining a drug treatment protocol for a subject suffering from chronic kidney disease.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: January 28, 2020
    Assignee: Randox Laboratories Ltd.
    Inventors: Ivan McConnell, Ciaran Richardson, John Lamont, Stephen Peter Fitzgerald
  • Cancer prevention and therapy by inhibiting soluble tumor necrosis factor
    Patent number: 10543264
    Abstract: Methods are disclosed for inhibiting the development of a tumor in a subject. The methods include administering to a subject a therapeutically effective amount of a dominant negative tumor necrosis factor (DN-TNF)-? protein and/or a nucleic acid encoding the DN-TNF-? protein. The DN-TNF-? protein and/or a nucleic acid encoding the DN-TNF-? protein can be administered alone or in combination with other agents.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: January 28, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nikola L. Vujanovic, Lazar Vujanovic
  • Affinity-based detection of ligand-encoded synthetic biomarkers
    Patent number: 10527619
    Abstract: The invention relates to methods and products associated with in vivo enzyme profiling. In particular, biomarker nanoparticles capable of quantitatively detecting enzymatic activity in vivo are described. These nanoparticles can be used to detect in vivo enzyme activity. The invention also relates to products, kits, and databases for use in the methods of the invention.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: January 7, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Sangeeta N. Bhatia, David K. Wood, Gabriel A. Kwong, Andrew D. Warren, Kevin Y. Lin
  • Compositions and methods for improved neurotoxin assays
    Patent number: 10526637
    Abstract: Methods for improving the specificity of assays for botulinum neurotoxins are described. Reporting constructs are provided that include cleavable linker sequence with genetically modified recognition and/or cleavage sites. These linker sequences act as a substrate for a botulinum neurotoxin, with cleavage of the reporting construct providing a detectable signal. When first and second neurotoxins have activity with the same substrate protein, mutation and/or deletion of a recognition and/or cleavage site associated with the second neurotoxin improves the specificity of the detectable signal for the first neurotoxin.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 7, 2020
    Assignee: BIOMADISON, INC.
    Inventors: Robert D. Fish, Min Dong
  • Method of screening for candidate compounds for regulating melanogenesis or pigmentation
    Patent number: 10520492
    Abstract: A method to identify target genes or proteins for regulating melanogenesis or pigmentation and to screen for compounds for manipulation of melanogenesis or pigmentation, the method of screening for candidate compounds for regulating melanogenesis or pigmentation, includes bringing test compounds into contact with cells capable of expressing mortalin and/or Hsp60 in vitro, and selecting, from among the test compounds, a compound that changes the expression level of mortalin and/or Hsp60.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: December 31, 2019
    Assignees: CHANEL PARFUMS BEAUTE, NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Renu Wadhwa, Sunil Kaul, Nobuhiro Ando, Christian Mahe
  • Protein sequencing method and reagents
    Patent number: 10481162
    Abstract: The invention describes methods and reagents useful for sequencing polypeptide molecules. The method comprises affixing a polypeptide to a substrate and contacting the polypeptide with a plurality of probes. Each probe selectively binds to an N-terminal amino acid or an N-terminal amino acid derivative. Probes bound to the polypeptide molecule are then identified before cleaving the N-terminal amino acid or N-terminal amino acid derivative of the polypeptide. Also provided are methods for the sequencing a plurality of polypeptide molecules in a sample and probes specific for N-terminal amino acids or N-terminal amino acid derivatives.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: November 19, 2019
    Assignee: The Governing Council of the University of Toronto
    Inventors: Andrew Emili, Megan McLaughlin, Kyrylo Zagorovsky, Jonathan Buchanan Olsen, Warren C. W. Chan, Sachdev S. Sidhu
  • Microfluidic cell culture of patient-derived tumor cell spheroids
    Patent number: 10472599
    Abstract: Provided herein are methods for culturing patient-derived tumor cell spheroids in a three-dimensional microfluidic device. The method comprises mincing primary tumor sample in a medium supplemented with serum; treating the minced primary tumor sample with a composition comprising an enzyme; collecting tumor spheroids having a diameter of 10 ?m to 500 ?m from the enzyme treated sample; suspending the tumor spheroids in biocompatible gel; and culturing the tumor spheroids in a three dimensional microfluidic device. Methods for identifying an agent for treating cancer and microfluidic devices that allow for the simultaneous exposure of the cultured patient-derived primary tumor cell spheroids to a treatment of choice and to control treatment are also provided.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: November 12, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: David Barbie, Amir Aref, Thanh Barbie, Russell W. Jenkins, Kwok-kin Wong
  • Prediction of the risk of developing a disseminated infection for patients admitted to an intensive care unit
    Patent number: 10466255
    Abstract: A method for predicting the risk of developing a disseminated infection in a patient admitted to intensive care having no clinical symptoms of such infection includes: determining a first dose of gelsolin G1 in a biological sample from the patient originating from a first sample taken at time T1, carried out between the day of intensive care admission and 48 hours afterward; determining a second dose of gelsolin G2 in a biological sample from the patient originating from a second sample taken at time T2, carried out two to three days after the first sampling; calculating the variation between the dose of gelsolin G2 and the dose of gelsolin G1, giving a ? value; and comparing the ? value to a threshold value S determined beforehand from two patient populations admitted to intensive care, one not having developed a disseminated infection and the other having developed such an infection.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: November 5, 2019
    Assignees: BIOMERIEUX, HOSPICES CIVILS DE LYON, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Bernard Allaouchiche, Karim Asehnoune, Marilyne Dupin, Tanguy Fortin, Aurélie Gouel-Cheron, Audrey Larue-Triolet, Guillaume Monneret, Alexandre Pachot, Sylvie Pons, Antoine Roquilly, Fabienne Venet
  • Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease
    Patent number: 10456364
    Abstract: Subject of the present invention are assays and in vitro methods for the in vitro diagnosis, prognosis and risk stratification of a patient having a primary, non-infectious disease, whereby the level of Procalcitonin (PCT) in a sample of a body fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: October 29, 2019
    Assignee: B.R.A.H.M.S. GmbH
    Inventors: Joachim Struck, Andreas Bergmann
  • Three-step acid dissociation enzyme linked immunosorbent (TADELIS) assay
    Patent number: 10458981
    Abstract: Herein is reported a method for determining in a sample the (total, i.e. binding competent) amount of a ligand of a ligand-binding protein (therapeutic) comprising the following steps in the following order: subjecting the sample to an acid treatment, forming in solution a non-covalent complex comprising i) an anti-ligand antibody, ii) the ligand, and iii) labelled ligand-binding protein, by adding anti-ligand antibody and labelled ligand-binding protein to the sample, and determining the amount of the complex and thereby determining the amount of the ligand of the ligand-binding protein.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: October 29, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Gregor Jordan, Roland Staack